MEDTEC Students against Coronavirus: Investigating the Role of Hemostatic Genes in the Predisposition to COVID-19 Severity

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent of the coronavirus disease 2019 (COVID-19) pandemic. Besides virus intrinsic characteristics, the host genetic makeup is predicted to account for the extreme clinical heterogeneity of the disease, which is characterized, among other manifestations, by a derangement of hemostasis associated with thromboembolic events. To date, large-scale studies confirmed that genetic predisposition plays a role in COVID-19 severity, pinpointing several susceptibility genes, often characterized by immunologic functions. With these premises, we performed an association study of common variants in 32 hemostatic genes with COVID-19 severity. We investigated 49,845 single-nucleotide polymorphism in a cohort of 332 Italian severe COVID-19 patients and 1668 controls from the general population. The study was conducted engaging a class of students attending the second year of the MEDTEC school (a six-year program, held in collaboration between Humanitas University and the Politecnico of Milan, allowing students to gain an MD in Medicine and a Bachelor’s Degree in Biomedical Engineering). Thanks to their willingness to participate in the fight against the pandemic, we evidenced several suggestive hits (p < 0.001), involving the PROC, MTHFR, MTR, ADAMTS13, and THBS2 genes (top signal in PROC: chr2:127192625:G:A, OR = 2.23, 95%CI = 1.50–3.34, p = 8.77 × 10−5). The top signals in PROC, MTHFR, MTR, ADAMTS13 were instrumental for the construction of a polygenic risk score, whose distribution was significantly different between cases and controls (p = 1.62 × 10−8 for difference in median levels). Finally, a meta-analysis performed using data from the Regeneron database confirmed the contribution of the MTHFR variant chr1:11753033:G:A to the predisposition to severe COVID-19 (pooled OR = 1.21, 95%CI = 1.09–1.33, p = 4.34 × 10−14 in the weighted analysis).

[1]  Mattia G. Bergomi,et al.  Mapping the human genetic architecture of COVID-19 , 2021, Nature.

[2]  K. Vanhoorelbeke,et al.  First report of a de novo iTTP episode associated with an mRNA‐based anti‐COVID‐19 vaccination , 2021, Journal of Thrombosis and Haemostasis.

[3]  S. Kaleci,et al.  COVID‐19 spreading across world correlates with C677T allele of the methylenetetrahydrofolate reductase (MTHFR) gene prevalence , 2021, Journal of clinical laboratory analysis.

[4]  I. Martín-Loeches,et al.  ADAMTS13 regulation of VWF multimer distribution in severe COVID‐19 , 2021, Journal of Thrombosis and Haemostasis.

[5]  M. Gisslén,et al.  Low admission protein C levels are a risk factor for disease worsening and mortality in hospitalized patients with COVID-19 , 2021, Thrombosis Research.

[6]  S. Scherer,et al.  Rare loss-of-function variants in type I IFN immunity genes are not associated with severe COVID-19. , 2021, The Journal of clinical investigation.

[7]  T. Mirault,et al.  Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance , 2021, Angiogenesis.

[8]  E. Simon,et al.  Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination , 2021, The American Journal of Emergency Medicine.

[9]  Ruth I. Tennen,et al.  Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severity , 2021, Nature Genetics.

[10]  P. Marco,et al.  Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19 , 2021, Journal of Thrombosis and Thrombolysis.

[11]  A. Coppola,et al.  Homocysteine (Hcy) assessment to predict outcomes of hospitalized Covid-19 patients: a multicenter study on 313 Covid-19 patients , 2021, Clinical chemistry and laboratory medicine.

[12]  V. Mootha,et al.  SARS-CoV-2 hijacks folate and one-carbon metabolism for viral replication , 2021, Nature Communications.

[13]  C. Tcherakian,et al.  ADAMTS 13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19 , 2021, Thrombosis Research.

[14]  Gregory J Krause,et al.  Low ADAMTS13 Activity Correlates with Increased Mortality in COVID-19 Patients , 2021, TH Open.

[15]  I. Martín-Loeches,et al.  Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID‐19): evidence of acute and sustained endothelial cell activation , 2020, British journal of haematology.

[16]  Alexander Hanbo Li,et al.  Genome-wide analysis in 756,646 individuals provides first genetic evidence that ACE2 expression influences COVID-19 risk and yields genetic risk scores predictive of severe disease , 2020, medRxiv.

[17]  Gustavo Faissol Janot de Matos,et al.  Coagulation profile of COVID-19 patients admitted to the ICU: An exploratory study , 2020, PloS one.

[18]  A. Alexandrov,et al.  COVID-19 and cerebrovascular diseases: a comprehensive overview , 2020, Therapeutic advances in neurological disorders.

[19]  S. Laporte,et al.  Prothrombotic hemostasis disturbances in patients with severe COVID-19: Individual daily data , 2020, Data in Brief.

[20]  Alexander Hanbo Li,et al.  A catalog of associations between rare coding variants and COVID-19 outcomes , 2020, medRxiv.

[21]  J. Knight,et al.  Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19 , 2020, Science Translational Medicine.

[22]  Barbara B. Shih,et al.  Genetic mechanisms of critical illness in COVID-19 , 2020, Nature.

[23]  Steven M. Holland,et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.

[24]  Jacques Fellay,et al.  Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.

[25]  M. Karst,et al.  Life-threatening course in coronavirus disease 2019 (COVID-19): Is there a link to methylenetetrahydrofolic acid reductase (MTHFR) polymorphism and hyperhomocysteinemia? , 2020, Medical Hypotheses.

[26]  G. Grasselli,et al.  Hemostatic alterations in COVID-19 , 2020, Haematologica.

[27]  D. Cummings,et al.  Age-specific mortality and immunity patterns of SARS-CoV-2 infection in 45 countries , 2020, medRxiv.

[28]  Jonathan A Stefely,et al.  Marked factor V activity elevation in severe COVID‐19 is associated with venous thromboembolism , 2020, American journal of hematology.

[29]  J. Merrill,et al.  Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications , 2020, Nature Reviews Rheumatology.

[30]  O. Olivieri,et al.  A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19 , 2020, Thrombosis Research.

[31]  Xiaowei Yan,et al.  Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients , 2020, Journal of Thrombosis and Thrombolysis.

[32]  G. Dangas,et al.  Viral Coagulopathy in Patients With COVID-19: Treatment and Care , 2020, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[33]  K. Bhaskaran,et al.  OpenSAFELY: factors associated with COVID-19 death in 17 million patients , 2020, Nature.

[34]  C. D. Dela Cruz,et al.  Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study , 2020, The Lancet Haematology.

[35]  J. Erdmann,et al.  Genomewide Association Study of Severe Covid-19 with Respiratory Failure , 2020, The New England journal of medicine.

[36]  P. Emery,et al.  Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia , 2020, The Lancet Rheumatology.

[37]  Mickaël Ohana,et al.  High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.

[38]  Koichi Yuki,et al.  COVID-19 pathophysiology: A review , 2020, Clinical Immunology.

[39]  G. Grasselli,et al.  Hypercoagulability of COVID‐19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis , 2020, Journal of Thrombosis and Haemostasis.

[40]  A. Mantovani,et al.  ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy , 2020, medRxiv.

[41]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[42]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[43]  P. Visscher,et al.  Genome-wide association study of medication-use and associated disease in the UK Biobank , 2019, Nature Communications.

[44]  L. Liang,et al.  Genetic overlap of chronic obstructive pulmonary disease and cardiovascular disease-related traits: a large-scale genome-wide cross-trait analysis , 2019, Respiratory Research.

[45]  Brian E. Cade,et al.  Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program , 2019, Nature.

[46]  C McRae,et al.  Myocardial infarction. , 2019, Australian family physician.

[47]  O. Andreassen,et al.  A global overview of pleiotropy and genetic architecture in complex traits , 2019, Nature Genetics.

[48]  Timothy Shin Heng Mak,et al.  Tutorial: a guide to performing polygenic risk score analyses , 2018, bioRxiv.

[49]  William J. Astle,et al.  Allelic Landscape of Human Blood Cell Trait Variation and Links , 2016 .

[50]  P. James,et al.  Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms , 2016, Journal of thrombosis and haemostasis : JTH.

[51]  Carson C Chow,et al.  Second-generation PLINK: rising to the challenge of larger and richer datasets , 2014, GigaScience.

[52]  A. Keinan,et al.  XWAS: A Software Toolset for Genetic Data Analysis and Association Studies of the X Chromosome , 2014, bioRxiv.

[53]  Christian Gieger,et al.  Genetic Variants in Novel Pathways Influence Blood Pressure and Cardiovascular Disease Risk , 2011, Nature.

[54]  P. Reitsma,et al.  Genetics of venous thrombosis , 2009, Journal of thrombosis and haemostasis : JTH.

[55]  Alberto Piazza,et al.  Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants , 2009, Nature Genetics.

[56]  X. Zheng,et al.  Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells , 2008, Journal of thrombosis and haemostasis : JTH.

[57]  Amitabh Sharma,et al.  Mining literature for a comprehensive pathway analysis: A case study for retrieval of homocysteine related genes for genetic and epigenetic studies , 2006, Lipids in Health and Disease.

[58]  Kristin K Nicodemus,et al.  Comparison of type I error for multiple test corrections in large single-nucleotide polymorphism studies using principal components versus haplotype blocking algorithms , 2005, BMC Genetics.

[59]  A. Bernardo,et al.  Hemostasis, Thrombosis, and Vascular Biology , 2022 .

[60]  D. Nyholt A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. , 2004, American journal of human genetics.

[61]  P. Durand,et al.  Acute methionine load‐induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage‐derived tissue factor activity in rats , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[62]  E. Lander,et al.  Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results , 1995, Nature Genetics.

[63]  G. Rodgers,et al.  Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[64]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[65]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[66]  S. Stouffer Adjustment during army life , 1977 .

[67]  J. Hemelrijk,et al.  Some remarks on the combination of independent tests , 1953 .